cbdMD (YCBD) Change in Receivables (2017 - 2025)
cbdMD (YCBD) reported Change in Receivables of $76755.0 for Q4 2025, down 73.44% on a YoY basis from $288936.0 in Q4 2024, and down 83.2% sequentially from $456916.0 in Q3 2025.
cbdMD (YCBD) Change in Receivables (2017 - 2025) Analysis & Trends
cbdMD (YCBD) has 9 years of Change in Receivables data on file, last reported at $76755.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Receivables fell 73.44% year-over-year to $76755.0; the trailing twelve-month figure through Dec 2025 stood at $227384.0 (up 27.57% YoY), and the FY2025 full-year result was $439565.0, up 347.14% from the prior year.
- Change in Receivables eased to $76755.0 in Q4 2025, from $456916.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $1.0 million in Q1 2021 to a low of -$815369.0 in Q2 2022.
- A 5-year average of $14412.3 and a median of -$27183.5 in 2021 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables jumped 13544.47% in 2021 and tumbled 11957.77% in 2022, its largest moves.
- Tracing YCBD's Change in Receivables over 5 years: stood at -$4554.0 in 2021, then plunged by 11957.77% to -$549111.0 in 2022, then jumped by 87.77% to -$67169.0 in 2023, then surged by 530.16% to $288936.0 in 2024, then sank by 73.44% to $76755.0 in 2025.
- Business Quant data shows YCBD's Change in Receivables at $76755.0 in Q4 2025, $456916.0 in Q3 2025, and -$84759.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | cbdMD | 438,678.80 | -2.95 Mn | 3.00 Mn | 76,755.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 76,755.00 |
| Dec 31, 2025 | 76,755.00 |
| Sep 30, 2025 | 456,916.00 |
| Sep 30, 2025 | 456,916.00 |
| Jun 30, 2025 | -84,759.00 |
| Jun 30, 2025 | -84,759.00 |
| Mar 31, 2025 | -221,528.00 |
| Mar 31, 2025 | -221,528.00 |
| Dec 31, 2024 | 288,936.00 |
| Dec 31, 2024 | 288,936.00 |
| Sep 30, 2024 | 75,503.00 |
| Sep 30, 2024 | 75,503.00 |
| Jun 30, 2024 | 47,771.00 |
| Jun 30, 2024 | 47,771.00 |
| Mar 31, 2024 | -233,963.00 |
| Mar 31, 2024 | -233,963.00 |
| Dec 31, 2023 | -67,169.00 |
| Dec 31, 2023 | -67,169.00 |
| Sep 30, 2023 | 57,609.00 |
| Sep 30, 2023 | 57,609.00 |